NRSN (NeuroSense Therapeutics) Other Financing: $-0.10 Mil (TTM As of Dec. 2025)


NRSN NeuroSense Therapeutics Ltd NRSN
29 GF Score
Price $0.77
! 2 Warning Signs
View Full Analysis

What is NeuroSense Therapeutics Other Financing?

NeuroSense Therapeutics NRSN +1.45% 29 Other Financing is $-0.10 Mil as of Dec. 2025. GuruFocus rates NRSN with a GF Score™ of 29/100. The stock has 2 warning signs investors should review.

NeuroSense Therapeutics's Other Financing for the six months ended in Dec. 2025 was $-0.05 Mil.

NeuroSense Therapeutics's Other Financing for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.10 Mil.

NeuroSense Therapeutics Other Financing Historical Data

* Premium members only.

The historical data trend for NeuroSense Therapeutics's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NeuroSense Therapeutics Other Financing Chart

NeuroSense Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Financing
Get a 7-Day Free Trial 2.04 3.85 -0.28 -0.39 -0.10

NeuroSense Therapeutics Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -0.08 -0.31 -0.05 -0.05
NRSN
29GF Score
NeuroSense Therapeutics Ltd NRSN
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NeuroSense Therapeutics Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-0.10 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of $-0.10 Mil mean?
NeuroSense Therapeutics (NRSN) has a Other Financing of $-0.10 Mil as of Dec. 2025. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for NeuroSense Therapeutics and its competitors.
Is NeuroSense Therapeutics' Other Financing too high?
NeuroSense Therapeutics' current Other Financing is $-0.10 Mil. Overall, NeuroSense Therapeutics has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does NeuroSense Therapeutics' Other Financing compare to SNTI and LSTA?
NeuroSense Therapeutics' Other Financing of $-0.10 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Biotechnology company?
A good Other Financing depends on the Biotechnology industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for NeuroSense Therapeutics and its competitors. NeuroSense Therapeutics's current Other Financing is $-0.10 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NeuroSense Therapeutics stock overvalued right now?
NeuroSense Therapeutics (NRSN) has a current Other Financing of $-0.10 Mil. The current Other Financing is $-0.10 Mil. NeuroSense Therapeutics' overall GF Score™ is 29/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For NeuroSense Therapeutics (NRSN), the current Other Financing is $-0.10 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

NeuroSense Therapeutics Business Description

Other Exchanges H1Z:Germany
Address 11 HaMenofim Street, Building B, Herzliya, ISR, 4672562
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
29GF Score

Get the complete analysis for NRSN

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.77
Price